Steven Anderson | Director, Office Of Biostatistics And Epidemiology
U.S. Food and Drug Administration (FDA)

Steven Anderson, Director, Office Of Biostatistics And Epidemiology, U.S. Food and Drug Administration (FDA)

Steve Anderson, Ph.D., M.P.P., is currently the Director of the Office of Biostatistics and Epidemiology (OBE) at the FDA Center for Biologics Evaluation and Research (CBER). He provides leadership for all CBER statistical, epidemiological and surveillance programs and has led numerous important surveillance and epidemiological studies and quantitative benefit-risk assessments of vaccines, tissues, and blood products using systems such as VAERS, the FDA Sentinel and CMS data. In 2017, Dr. Anderson led CBER efforts to launch the Biologics Effectiveness and Safety (BEST) system, CBER’s new postmarket risk identification and analysis system that engages new data sources, tools, new innovative technologies such as artificial intelligence, and experts to further enhance biologic product effectiveness and safety surveillance.

Dr. Anderson earned a Master’s Degree in Public Policy (MPP) at Georgetown University and his PhD from the University of Cincinnati where he worked in the areas of biochemistry, drug resistance and ion pumps, pathogenicity and genomics of unique tropical disease pathogens. He has published a number of articles in biologic product safety, surveillance, risk assessment, epidemiology, infectious diseases, biologics safety, and genomics.


Day 2, April 8 @ 16:40

Post-marketing assessment of vaccine safety in pregnancy

  • Key issues surrounding post-marketing safety surveillance for vaccines used during pregnancy
  • Update on changes in recently published Post-approval Pregnancy Safety Studies
last published: 05/Mar/20 10:35 GMT

back to speakers

Sign Up for Event Updates